Alnylam Pharmaceuticals vs Ionis Pharmaceuticals
ALNY and IONS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALNY and IONS compare
Alnylam Pharmaceuticals is the larger company, worth 4.7 times as much as Ionis Pharmaceuticals ($21.0B against $4.5B).
Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus −7.4% for Ionis Pharmaceuticals).
Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with −64.7% at Ionis Pharmaceuticals.
Alnylam Pharmaceuticals scores higher on the StockData Score (10 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALNY | IONS |
|---|---|---|
| Size and price | ||
| Market cap | $21.0B | $4.5B |
| Share price | $156.50 | $26.96 |
| Change, 1 year | −65.2% | −62.3% |
| Change, 5 years | −17.0% | −7.2% |
| Beta (5Y) | 0.92 | 0.60 |
| Employees | 2,500 | 1,402 |
| StockData Score | ||
| Total score | 10 (better) | 4 |
| Valuation score | 3 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 0 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.1× | – |
| P/S | 4.2× (better) | 5.1× |
| P/B | 5.8× (better) | 10.2× |
| EV/EBITDA | 16.8× | – |
| P/FCF | 26.0× | – |
| FCF yield | 3.8% (better) | −12.5% |
| Fair value | $296.91 | $27.86 |
| Margin of safety | 47.3% (better) | 3.2% |
| Growth | ||
| Revenue growth (TTM) | 56.2% (better) | −7.4% |
| Revenue growth, 5Y average | 49.8% (better) | 5.3% |
| Net income growth (TTM) | 2137% | – |
| EPS growth (TTM) | 2308% | – |
| Profitability | ||
| Gross margin | 77.4% | 98.2% (better) |
| Operating margin | 19.5% (better) | −68.0% |
| Net margin | 52.8% (better) | −64.7% |
| FCF margin | 16.1% (better) | −64.2% |
| Return on equity | 127% (better) | −105% |
| Financial health | ||
| Interest coverage | 3.2× (better) | −31.6× |
| Current ratio | 2.48 | 7.89 (better) |
| Altman Z-score | 3.62 (better) | 0.23 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.7% | 108% |
| Held by insiders | 0.49% | 0.81% |
| Insider net buying, 12 months | −$26.3M (better) | −$114M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.1% | 12.8% |
Go deeper
- ALNY stock overview
- ALNY income statement
- ALNY valuation and score
- IONS stock overview
- IONS income statement
- IONS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.